metabolic effects [phsf]
Beta [plnt]
nebivolol [orch, phsu]
Metoprolol [orch, phsu]
Patients [podg]
Hypertension [dsyn]
Ischaemic [ftcn]
Heart disease [dsyn]
Combined [qlco]
Type 2 Diabetes [dsyn]
Efficacy [qlco]
Safety [hcpp]
Beta [plnt]
nebivolol [orch, phsu]
Metoprolol [orch, phsu]
Patients [podg]
Hypertension [dsyn]
ischaemic heart disease [dsyn]
Combined [qlco]
Type 2 Diabetes [dsyn]
Material [sbst]
Methods [inpr]
Patients [podg]
ischaemic heart disease [dsyn]
Angina, class II [dsyn]
III [inpr]
Moderately [qlco]
Severe [qlco]
Compensated [qlco]
Type 2 Diabetes [dsyn]
N NOS [aapp, imft]
Grade 1 Hypertension [fndg]
Classification [clas]
divided [ftcn]
Group [idcn]
Laboratory [mnob, orgt]
Characteristics [qlco]
Patients [podg]
Group I [inpr]
Received [qlco]
Metoprolol [orch, phsu]
mg day [qnco]
Group 2 [inpr]
nebivolol [orch, phsu]
mg day [qnco]
weeks [tmco]
Physical [hlca]
Investigation [hlca]
Exercise Tests [diap]
24 hour blood pressure [orgf]
Heart rate monitoring [diap]
Lipid [lipd]
Spectrum [qnco]
glycemia [carb]
Profile [lbpr]
Assessment [hlca]
Treatment Efficacy [qlco]
Decrease [qlco]
anginal attacks [dsyn]
Nitroglycerin [orch, phsu]
Requirement [ftcn]
nebivolol [orch, phsu]
treated [topp]
Patients [podg]
Drugs [phsu]
lowering [spco]
Blood Pressure [orgf]
heart rate [clna]
Unfavorable [qlco]
Parameters [fndg]
Carbohydrate [carb]
Lipid Metabolism [moft]
lowering [spco]
Triglycerides [bacs, lipd]
Observed [ftcn]
nebivolol [orch, phsu]
treated [topp]
Patients [podg]
Drugs [phsu]
Well [qlco]
nebivolol [orch, phsu]
Metoprolol [orch, phsu]
effective [qlco]
Anti-anginal Agent [phsu]
Patients [podg]
ischaemic heart disease [dsyn]
Hypertension [dsyn]
Combined [qlco]
Type 2 Diabetes [dsyn]
Doses [qnco]
nebivolol [orch, phsu]
Favorable [qlco]
Metabolic [ftcn]
Hemodynamic [ortf]
effects [qlco]
